Compare Gilead Sciences, Inc. (GILD) vs Tesla, Inc. (TSLA) Price & Performance

Gilead Sciences, Inc.Trade

Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Tesla, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while Tesla, Inc. trades at $334.01 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 7.9× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.

	GILD	TSLA
Market Cap	$164.99B	$1.31T
Sector	Health	Consumer Cyclical
52-Week High	$155.80	$489.88
52-Week Low	$110.56	$298.16
Enterprise Value	$188.06B	$1.28T
Dividend Yield	2.47%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

No Aura AI signal available yet.

Tesla, Inc.

Tesla (TSLA) trades at $330.87, up 0.7% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key resistance at $333 and support at $327, while fundamentals reveal high valuation multiples (P/E 306.37) and declining profit margins (net margin 3.67% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing near-term delivery misses with long-term innovation bets.

Tesla's outlook hinges on executing its pivot to AI and autonomy amid slowing auto growth. Investment opportunities lie in market leadership in self-driving technology and energy expansion, but risks include intense EV competition, execution challenges, and rich valuations that demand flawless growth. Wall Street remains divided, with a $393.87 consensus target suggesting upside if catalysts materialize.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 1 day agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

TSLA

Humanoid robot boom drives huge memory demand, spotlighting Micron as key supplier amid tight DRAM supply.24/7 Wall Street · 20 hours agoBullish Unitree's $900M IPO oversubscribed 8,000x signals booming investor interest in physical AI robotics.24/7 Wall Street · 21 hours agoBullish Nio shares drop 5% after BlackRock reduces stake despite strong delivery growth.24/7 Wall Street · 22 hours agoBearish View details →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.